<DOC>
	<DOC>NCT00207116</DOC>
	<brief_summary>The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer</brief_summary>
	<brief_title>An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Measurable disease tumor available for biopsies Life expectancy of at least 3 months Known or documented brain metastases prior to Cetuximab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Metastatic Non Small Cell Lung Cancer</keyword>
</DOC>